• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌的常规细胞学亚型:国际肺癌研究协会细胞学工作组调查结果,旨在确定腺癌和鳞状细胞癌的特定细胞学形态学标准。

NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma.

机构信息

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

出版信息

J Thorac Oncol. 2022 Jun;17(6):793-805. doi: 10.1016/j.jtho.2022.02.013. Epub 2022 Mar 22.

DOI:10.1016/j.jtho.2022.02.013
PMID:35331963
Abstract

INTRODUCTION

Accurate subtyping of NSCLC into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is the cornerstone of NSCLC diagnosis. Cytology samples reveal higher rates of classification failures, that is, subtyping as non-small cell carcinoma-not otherwise specified (NSCC-NOS), as compared with histology specimens. This study aims to identify specific algorithms on the basis of known cytomorphologic features that aid accurate and successful subtyping of NSCLC on cytology.

METHODS

A total of 13 expert cytopathologists participated anonymously in an online survey to subtype 119 NSCLC cytology cases (gold standard diagnoses being LUAD in 80 and LUSC in 39) enriched for nonkeratinizing LUSC. They selected from 23 predefined cytomorphologic features that they used in subtyping. Data were analyzed using machine learning algorithms on the basis of random forest method and regression trees.

RESULTS

From 1474 responses recorded, concordant cytology typing was achieved in 53.7% (792 of 1474) responses. NSCC-NOS rates on cytology were similar among gold standard LUAD (36%) and LUSC (38%) cases. Misclassification rates were higher in gold standard LUSC (17.6%) than gold standard LUAD (5.5%; p < 0.0001). Keratinization, when present, recognized LUSC with high accuracy. In its absence, the machine learning algorithms developed on the basis of experts' choices were unable to reduce cytology NSCC-NOS rates without increasing misclassification rates.

CONCLUSIONS

Suboptimal recognition of LUSC in the absence of keratinization remains the major hurdle in improving cytology subtyping accuracy with such cases either failing classification (NSCC-NOS) or misclassifying as LUAD. NSCC-NOS seems to be an inevitable morphologic diagnosis emphasizing that ancillary immunochemistry is necessary to achieve accurate subtyping on cytology.

摘要

简介

准确地将 NSCLC 分为肺腺癌 (LUAD) 和肺鳞状细胞癌 (LUSC) 是 NSCLC 诊断的基石。与组织学标本相比,细胞学样本显示出更高的分类失败率,即分类为非小细胞癌-非特指型 (NSCC-NOS)。本研究旨在根据已知的细胞形态学特征,确定特定的算法,以帮助准确、成功地对细胞学标本进行 NSCLC 分型。

方法

共有 13 位细胞病理专家匿名参与了一项在线调查,对 119 例 NSCLC 细胞学病例进行亚型分类(80 例为 LUAD,39 例为 LUSC),这些病例富含非角化性 LUSC。他们从 23 个预先定义的细胞形态学特征中选择用于分类的特征。数据使用随机森林方法和回归树的机器学习算法进行分析。

结果

在记录的 1474 次应答中,53.7%(792/1474)的应答达到了一致的细胞学分型。金标准 LUAD(36%)和 LUSC(38%)病例的细胞学 NSCC-NOS 发生率相似。金标准 LUSC (17.6%)的误诊率高于金标准 LUAD(5.5%;p<0.0001)。角化存在时,可准确识别 LUSC。角化不存在时,基于专家选择开发的机器学习算法无法在不增加误诊率的情况下降低细胞学 NSCC-NOS 率。

结论

在缺乏角化的情况下,对 LUSC 的识别不理想仍然是提高细胞学分型准确性的主要障碍,这些病例要么分类失败(NSCC-NOS),要么误诊为 LUAD。NSCC-NOS 似乎是一种不可避免的形态学诊断,强调需要辅助免疫化学来实现细胞学的准确分型。

相似文献

1
NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma.非小细胞肺癌的常规细胞学亚型:国际肺癌研究协会细胞学工作组调查结果,旨在确定腺癌和鳞状细胞癌的特定细胞学形态学标准。
J Thorac Oncol. 2022 Jun;17(6):793-805. doi: 10.1016/j.jtho.2022.02.013. Epub 2022 Mar 22.
2
Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.中国非小细胞肺癌患者中腺癌和鳞状细胞癌主要组织学亚型的突变特征比较研究。
Thorac Cancer. 2020 Jan;11(1):103-112. doi: 10.1111/1759-7714.13208. Epub 2019 Nov 6.
3
Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.非小细胞肺癌的亚型分类:小活检和细胞学标本的比较。
J Thorac Oncol. 2011 Nov;6(11):1849-56. doi: 10.1097/JTO.0b013e318227142d.
4
Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.TOP2A 和 ADH1B 与肺腺癌和肺鳞癌患者的血脂水平及预后的关系。
Clin Respir J. 2023 Dec;17(12):1301-1315. doi: 10.1111/crj.13717. Epub 2023 Nov 20.
5
A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.多组学整合分析早期非小细胞肺癌的预后相关分子亚型。
BMC Cancer. 2021 Feb 6;21(1):128. doi: 10.1186/s12885-021-07846-0.
6
Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.胸部分泌细胞学在非小细胞肺癌新治疗模式中的适用性:肿瘤亚型分类的高准确性和 EGFR、KRAS 分子检测的可行性。
J Thorac Oncol. 2011 Mar;6(3):451-8. doi: 10.1097/JTO.0b013e31820517a3.
7
Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.非小细胞肺癌差异表达 miRNA 的生物信息学分析。
J Clin Lab Anal. 2021 Feb;35(2):e23588. doi: 10.1002/jcla.23588. Epub 2020 Sep 23.
8
Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.血液中叶酸受体3(FOLR3)甲基化失调及非小细胞肺癌中的异质性突显了其与肺鳞状细胞癌的紧密关联。
Respir Res. 2024 Jan 25;25(1):59. doi: 10.1186/s12931-024-02691-8.
9
Diagnostic utility of fine needle aspiration cytology and core biopsy histopathology with or without immunohistochemical staining in the subtyping of the non-small cell lung carcinomas: Experience from an academic centre in Turkey.细针穿刺细胞学检查及粗针活检组织病理学检查(无论有无免疫组化染色)在非小细胞肺癌亚型诊断中的应用:来自土耳其某学术中心的经验
Cytopathology. 2021 May;32(3):331-337. doi: 10.1111/cyt.12937. Epub 2020 Dec 8.
10
What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients.肺腺癌和肺鳞状细胞癌有什么区别?来自中国患者队列回顾性分析的证据。
Front Endocrinol (Lausanne). 2022 Aug 29;13:947443. doi: 10.3389/fendo.2022.947443. eCollection 2022.

引用本文的文献

1
Identifying ferroptosis-related genes in lung adenocarcinoma using random walk with restart in the PPI network.利用PPI网络中带重启的随机游走算法识别肺腺癌中铁死亡相关基因。
Sci Rep. 2025 Aug 6;15(1):28832. doi: 10.1038/s41598-025-14307-2.
2
Machine learning enabled classification of lung cancer cell lines co-cultured with fibroblasts with lightweight convolutional neural network for initial diagnosis.机器学习通过轻量级卷积神经网络对与成纤维细胞共培养的肺癌细胞系进行分类,用于初步诊断。
J Biomed Sci. 2024 Aug 23;31(1):84. doi: 10.1186/s12929-024-01071-0.
3
Distinctive field effects of smoking and lung cancer case-control status on bronchial basal cell growth and signaling.
吸烟和肺癌病例对照状态对支气管基底细胞生长和信号的独特影响。
Respir Res. 2024 Aug 19;25(1):317. doi: 10.1186/s12931-024-02924-w.
4
AI/ML advances in non-small cell lung cancer biomarker discovery.人工智能/机器学习在非小细胞肺癌生物标志物发现方面的进展。
Front Oncol. 2023 Dec 11;13:1260374. doi: 10.3389/fonc.2023.1260374. eCollection 2023.
5
Unlocking the predictive potential of long non-coding RNAs: a machine learning approach for precise cancer patient prognosis.解锁长非编码 RNA 的预测潜力:一种用于精确癌症患者预后的机器学习方法。
Ann Med. 2023;55(2):2279748. doi: 10.1080/07853890.2023.2279748. Epub 2023 Nov 20.
6
Clinicopathological and prognostic significance of SMAD4 in non-small cell lung cancer: A meta-analysis and database validation.SMAD4 在非小细胞肺癌中的临床病理及预后意义:Meta 分析及数据库验证。
Medicine (Baltimore). 2023 Jul 21;102(29):e34312. doi: 10.1097/MD.0000000000034312.
7
Accuracy of Classifying Lung Carcinoma Using Immunohistochemical Markers on Limited Biopsy Material: A Two-Center Study.利用有限活检材料上的免疫组织化学标志物对肺癌进行分类的准确性:一项双中心研究。
Cureus. 2022 Dec 26;14(12):e32956. doi: 10.7759/cureus.32956. eCollection 2022 Dec.